Mergers & acquisitions
Leading Patient Experience Platform Advances Company’s Market Position
Merck plunked down $576 million to acquire San Diego-based Calporta to gain access to preclinical TRPML1 agonists that are seen as potential treatments for neurodegenerative disorders such as Alzheimer’s or Parkinson’s.
Expedeon AG announces the signing of an agreement with Abcam plc, Cambridge, UK, to sell its proteomics and immunology business activities for a cash payment of EUR 120 million.
The merged company will be led by David Domzalski, current chief executive officer of Foamix. It will be headquartered in New Jersey.
Novartis said the acquisition will enable Sandoz to expand its presence in the third-largest worldwide generics marketplace.
The agreement was formally signed yesterday.
SP Industries, Inc., a leading designer and manufacturer of state-of-the-art laboratory equipment, pharmaceutical fill-finish manufacturing solutions, laboratory supplies and glassware, announced that it has acquired the assets of privately held i-Dositecno.
This marks the eighth such extension for the deal.
Edan Diagnostics, Inc., a wholly own subsidiary of Edan Instruments, Inc., a world leader in the development and manufacture of bio-electronic devices and laboratory analyzers for medical diagnostics, and LGC, a global life science tools leader, announced today the sale of LGC’s ClariLight molecular diagnostics POC platform to Edan.
Founder Mike Wenger to Join Staff as Vice President of Patient Engagement
PRESS RELEASES